Clinical Trials Logo

Clinical Trial Summary

This is a study to evaluate the efficacy and safety of TQB2450 injection in the treatment of PD-L1 positive recurrent or metastatic cervical cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04623333
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Beihua Kong, Doctor
Phone 0531-82166671
Email kongbeihua@sdu.edu.cn
Status Not yet recruiting
Phase Phase 2
Start date November 30, 2020
Completion date June 30, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06155422 - A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer
Active, not recruiting NCT04680988 - A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer Phase 2
Completed NCT04868708 - A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer Phase 2